Compare SSL & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSL | PTCT |
|---|---|---|
| Founded | 1950 | 1998 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 5.3B |
| IPO Year | N/A | 2013 |
| Metric | SSL | PTCT |
|---|---|---|
| Price | $5.99 | $77.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $73.76 |
| AVG Volume (30 Days) | 945.5K | ★ 2.3M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.59 | ★ 8.94 |
| Revenue | ★ $14,028,282,389.00 | $1,779,150,000.00 |
| Revenue This Year | $1.17 | $128.32 |
| Revenue Next Year | $6.50 | N/A |
| P/E Ratio | $10.13 | ★ $8.64 |
| Revenue Growth | N/A | ★ 97.54 |
| 52 Week Low | $2.78 | $35.95 |
| 52 Week High | $7.39 | $87.50 |
| Indicator | SSL | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 54.29 |
| Support Level | $6.27 | $73.03 |
| Resistance Level | $6.46 | $79.03 |
| Average True Range (ATR) | 0.15 | 3.38 |
| MACD | -0.11 | -0.70 |
| Stochastic Oscillator | 2.11 | 29.37 |
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.